{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:10:18Z","timestamp":1793110218677,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-70859-5","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:07:05Z","timestamp":1773752825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Programmable nanomicelles rewire myeloid immunity for durable control of primary and metastatic breast cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-2015","authenticated-orcid":false,"given":"Jie","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0453-4862","authenticated-orcid":false,"given":"Yingbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoshuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3390-1254","authenticated-orcid":false,"given":"Zhiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6385-0942","authenticated-orcid":false,"given":"Yize","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6071-0878","authenticated-orcid":false,"given":"Jinbing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3311-7403","authenticated-orcid":false,"given":"Zebin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-7865","authenticated-orcid":false,"given":"Shenghong","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"70859_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA A Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA A Cancer J. Clin."},{"key":"70859_CR2","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(24)01745-8","volume":"404","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2024","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155\u2008746 women in 151 trials. Lancet 404, 1407\u20131418 (2024).","journal-title":"Lancet"},{"key":"70859_CR3","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1172\/JCI75661","volume":"124","author":"TU Barbie","year":"2014","unstructured":"Barbie, T. U. et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.  J. Clin. Investig. 124, 5411\u20135423 (2014).","journal-title":"J. Clin. Investig."},{"key":"70859_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41591-020-01189-2","volume":"27","author":"T Bachelot","year":"2021","unstructured":"Bachelot, T. et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat. Med. 27, 250\u2013255 (2021).","journal-title":"Nat. Med."},{"key":"70859_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","volume":"30","author":"Z Jiang","year":"2024","unstructured":"Jiang, Z. et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat. Med. 30, 249\u2013256 (2024).","journal-title":"Nat. Med."},{"key":"70859_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","volume":"35","author":"R Dent","year":"2024","unstructured":"Dent, R. et al. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 35, 630\u2013642 (2024).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"70859_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","volume":"41","author":"L van Vlerken-Ysla","year":"2023","unstructured":"van Vlerken-Ysla, L., Tyurina, Y. Y., Kagan, V. E. & Gabrilovich, D. I. Functional states of myeloid cells in cancer. Cancer cell 41, 490\u2013504 (2023).","journal-title":"Cancer cell"},{"key":"70859_CR8","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris, M. A. et al. Towards targeting the breast cancer immune microenvironment. Nat. Rev. Cancer 24, 554\u2013577 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"70859_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.immuni.2021.03.022","volume":"54","author":"E G\u00fc\u00e7","year":"2021","unstructured":"G\u00fc\u00e7, E. & Pollard, J. W. Redefining macrophage and neutrophil biology in the metastatic cascade. Immunity 54, 885\u2013902 (2021).","journal-title":"Immunity"},{"key":"70859_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"70859_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-022-01335-y","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E. & Li, Z. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. J. Hematol. Oncol. 15, 118 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"70859_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991\u2013998 (2002).","journal-title":"Nat. Immunol."},{"key":"70859_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","volume":"35","author":"L Cassetta","year":"2019","unstructured":"Cassetta, L. et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer cell 35, 588\u2013602.e510 (2019).","journal-title":"Cancer cell"},{"key":"70859_CR14","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.immuni.2024.08.015","volume":"57","author":"Z Nian","year":"2024","unstructured":"Nian, Z. et al. Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation. Immunity 57, 2344\u20132361.e2347 (2024).","journal-title":"Immunity"},{"key":"70859_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie, Y., Tang, F., Wei, Y. Q. & Wei, X. W. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J. Hematol. Oncol. 15, 61 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"70859_CR16","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.it.2024.08.005","volume":"45","author":"VS Gogoleva","year":"2024","unstructured":"Gogoleva, V. S., Mundt, S., De Feo, D. & Becher, B. Mononuclear phagocytes in autoimmune neuroinflammation. Trends Immunol. 45, 814\u2013823 (2024).","journal-title":"Trends Immunol."},{"key":"70859_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nature02238","volume":"427","author":"TR Mempel","year":"2004","unstructured":"Mempel, T. R., Henrickson, S. E. & Von Andrian, U. H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427, 154\u2013159 (2004).","journal-title":"Nature"},{"key":"70859_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41565-022-01296-w","volume":"18","author":"SM Jin","year":"2023","unstructured":"Jin, S. M. et al. A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion. Nat. Nanotechnol. 18, 390\u2013402 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"70859_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41577-024-01079-5","volume":"25","author":"V Bosteels","year":"2024","unstructured":"Bosteels, V. & Janssens, S. Striking a balance: new perspectives on homeostatic dendritic cell maturation. Nat. Rev. Immunol. 25, 125\u2013140 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"70859_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41565-023-01553-6","volume":"19","author":"G Liu","year":"2024","unstructured":"Liu, G. et al. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity. Nat. Nanotechnol. 19, 387\u2013398 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"70859_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/imr.13050","volume":"306","author":"B Bo\u0161njak","year":"2022","unstructured":"Bo\u0161njak, B., Do, K. T. H., F\u00f6rster, R. & Hammerschmidt, S. I. Imaging dendritic cell functions. Immunol. Rev. 306, 137\u2013163 (2022).","journal-title":"Immunol. Rev."},{"key":"70859_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487\u2013500 (2022).","journal-title":"Nat. Immunol."},{"key":"70859_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41588-021-00778-2","volume":"53","author":"E Papalexi","year":"2021","unstructured":"Papalexi, E. et al. Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens. Nat. Genet. 53, 322\u2013331 (2021).","journal-title":"Nat. Genet."},{"key":"70859_CR24","doi-asserted-by":"publisher","first-page":"E933","DOI":"10.1073\/pnas.1319493111","volume":"111","author":"BQ Spring","year":"2014","unstructured":"Spring, B. Q. et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc. Natl. Acad. Sci. USA 111, E933\u2013E942 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70859_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn2941","volume":"8","author":"Y Guo","year":"2022","unstructured":"Guo, Y. et al. Copackaging photosensitizer and PD-L1 siRNA in a nucleic acid nanogel for synergistic cancer photoimmunotherapy. Sci. Adv. 8, eabn2941 (2022).","journal-title":"Sci. Adv."},{"key":"70859_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ejmech.2018.10.044","volume":"161","author":"T Chen","year":"2019","unstructured":"Chen, T. et al. Peptide-based and small synthetic molecule inhibitors on PD-1\/PD-L1 pathway: a new choice for immunotherapy? Eur. J. Med. Chem. 161, 378\u2013398 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"70859_CR27","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides, A. et al. The complex role of tumor-infiltrating macrophages. Nat. Immunol. 23, 1148\u20131156 (2022).","journal-title":"Nat. Immunol."},{"key":"70859_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","volume":"16","author":"M Li","year":"2023","unstructured":"Li, M. et al. Metabolism, metabolites, and macrophages in cancer. J. Hematol. Oncol. 16, 80 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"70859_CR29","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41565-023-01523-y","volume":"18","author":"S Koo","year":"2023","unstructured":"Koo, S. et al. Ceria-vesicle nanohybrid therapeutic for modulation of innate and adaptive immunity in a collagen-induced arthritis model. Nat. Nanotechnol. 18, 1502\u20131514 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"70859_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007253","volume":"11","author":"YN Wang","year":"2023","unstructured":"Wang, Y. N. et al. Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response. J. Immunother. Cancer 11, e007253 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"70859_CR31","doi-asserted-by":"publisher","first-page":"eaax6337","DOI":"10.1126\/scitranslmed.aax6337","volume":"12","author":"JM Jaynes","year":"2020","unstructured":"Jaynes, J. M. et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci. Transl. Med. 12, eaax6337 (2020).","journal-title":"Sci. Transl. Med."},{"key":"70859_CR32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","volume":"19","author":"MJ Pittet","year":"2022","unstructured":"Pittet, M. J., Michielin, O. & Migliorini, D. Clinical relevance of tumour-associated macrophages. Nat. Rev. Clin. Oncol. 19, 402\u2013421 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70859_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl3649","volume":"14","author":"Y Song","year":"2022","unstructured":"Song, Y. et al. Albumin nanoparticle containing a PI3K\u03b3 inhibitor and paclitaxel in combination with \u03b1-PD1 induces tumor remission of breast cancer in mice. Sci. Transl. Med. 14, eabl3649 (2022).","journal-title":"Sci. Transl. Med."},{"key":"70859_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01313-x","volume":"20","author":"S Mohapatra","year":"2021","unstructured":"Mohapatra, S., Pioppini, C., Ozpolat, B. & Calin, G. A. Non-coding RNAs regulation of macrophage polarization in cancer. Mol. Cancer 20, 24 (2021).","journal-title":"Mol. Cancer"},{"key":"70859_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle, M., El-Daly, S. M., Fabbri, M. & Calin, G. A. Noncoding RNA therapeutics\u2014challenges and potential solutions. Nat. Rev. Drug Discov. 20, 629\u2013651 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70859_CR36","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/2159-8290.CD-23-0299","volume":"13","author":"I Yofe","year":"2023","unstructured":"Yofe, I. et al. Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary. Cancer Discov. 13, 2610\u20132631 (2023).","journal-title":"Cancer Discov."},{"key":"70859_CR37","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/15384047.2018.1456599","volume":"19","author":"L Jin","year":"2018","unstructured":"Jin, L. et al. Breast cancer lung metastasis: molecular biology and therapeutic implications. Cancer Biol. Ther. 19, 858\u2013868 (2018).","journal-title":"Cancer Biol. Ther."},{"key":"70859_CR38","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1016\/j.cell.2024.09.016","volume":"187","author":"E Dalla","year":"2024","unstructured":"Dalla, E. et al. Lung-resident alveolar macrophages regulate the timing of breast cancer metastasis. Cell 187, 6631\u20136648.e6620 (2024).","journal-title":"Cell"},{"key":"70859_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1049023","volume":"2017","author":"V Kaewkangsadan","year":"2017","unstructured":"Kaewkangsadan, V. et al. The differential contribution of the innate immune system to a good pathological response in the breast and axillary lymph nodes induced by neoadjuvant chemotherapy in women with large and locally advanced breast cancers. J. Immunol. Res. 2017, 1049023 (2017).","journal-title":"J. Immunol. Res."},{"key":"70859_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001352","volume":"8","author":"JM Versluis","year":"2020","unstructured":"Versluis, J. M., Thommen, D. S. & Blank, C. U. Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach. J. Immunother. cancer 8, e001352 (2020).","journal-title":"J. Immunother. cancer"},{"key":"70859_CR41","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.cell.2021.09.006","volume":"184","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell 184, 5357\u20135374.e5322 (2021).","journal-title":"Cell"},{"key":"70859_CR42","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.  J. Clin. Investig. 121, 2750\u20132767 (2011).","journal-title":"J. Clin. Investig."},{"key":"70859_CR43","doi-asserted-by":"publisher","first-page":"1153990","DOI":"10.3389\/fimmu.2023.1153990","volume":"14","author":"Y Zheng","year":"2023","unstructured":"Zheng, Y., Li, S., Tang, H., Meng, X. & Zheng, Q. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. Front. Immunol. 14, 1153990 (2023).","journal-title":"Front. Immunol."},{"key":"70859_CR44","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdy024","volume":"29","author":"Y Bareche","year":"2018","unstructured":"Bareche, Y. et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 29, 895\u2013902 (2018).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"70859_CR45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-025-00798-8","volume":"25","author":"Z Xiao","year":"2025","unstructured":"Xiao, Z. & Pur\u00e9, E. The fibroinflammatory response in cancer. Nat. Rev. Cancer 25, 399\u2013425 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"70859_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura, K. & Smyth, M. J. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell. Mol. Immunol. 17, 1\u201312 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"70859_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","volume":"23","author":"S Goswami","year":"2023","unstructured":"Goswami, S., Anandhan, S., Raychaudhuri, D. & Sharma, P. Myeloid cell-targeted therapies for solid tumours. Nat. Rev. Immunol. 23, 106\u2013120 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"70859_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev-immunol-042718-041728","volume":"37","author":"K Bassler","year":"2019","unstructured":"Bassler, K., Schulte-Schrepping, J., Warnat-Herresthal, S., Aschenbrenner, A. C. & Schultze, J. L. The myeloid cell compartment-cell by cell. Annu. Rev. Immunol. 37, 269\u2013293 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"70859_CR49","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889\u2013896 (2010).","journal-title":"Nat. Immunol."},{"key":"70859_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg2697","volume":"9","author":"S Han","year":"2023","unstructured":"Han, S. et al. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci. Adv. 9, eadg2697 (2023).","journal-title":"Sci. Adv."},{"key":"70859_CR51","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1021\/acsnano.3c06987","volume":"18","author":"P Zheng","year":"2024","unstructured":"Zheng, P. et al. Engineered bacterial biomimetic vesicles reprogram tumor-associated macrophages and remodel tumor microenvironment to promote innate and adaptive antitumor immune responses. ACS Nano 18, 6863\u20136886 (2024).","journal-title":"ACS Nano"},{"key":"70859_CR52","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jconrel.2021.09.011","volume":"338","author":"A Uno","year":"2021","unstructured":"Uno, A. et al. A novel \u03b2-glucan-oligonucleotide complex selectively delivers siRNA to APCs via Dectin-1. J. Control. Release. Off. J. Control. Release. Soc. 338, 792\u2013803 (2021).","journal-title":"J. Control. Release. Off. J. Control. Release. Soc."},{"key":"70859_CR53","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"70859_CR54","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1158\/0008-5472.CAN-05-0426","volume":"65","author":"MD Savellano","year":"2005","unstructured":"Savellano, M. D., Pogue, B. W., Hoopes, P. J., Vitetta, E. S. & Paulsen, K. D. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res. 65, 6371\u20136379 (2005).","journal-title":"Cancer Res."},{"key":"70859_CR55","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253\u2013268 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"70859_CR56","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.1073\/pnas.1916249117","volume":"117","author":"D Basavarajappa","year":"2020","unstructured":"Basavarajappa, D. et al. Dicer up-regulation by inhibition of specific proteolysis in differentiating monocytic cells. Proc. Natl. Acad. Sci. USA 117, 8573\u20138583 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70859_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0563-x","volume":"16","author":"A Spitschak","year":"2017","unstructured":"Spitschak, A., Meier, C., Kowtharapu, B., Engelmann, D. & P\u00fctzer, B. M. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-\u03baB to loss of the HES1\/Notch1 regulatory circuit. Mol. Cancer 16, 24 (2017).","journal-title":"Mol. Cancer"},{"key":"70859_CR58","doi-asserted-by":"publisher","first-page":"11449","DOI":"10.1073\/pnas.1411393111","volume":"111","author":"JE Zuckerman","year":"2014","unstructured":"Zuckerman, J. E. et al. Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl. Acad. Sci. USA 111, 11449\u201311454 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70859_CR59","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.tibtech.2018.02.014","volume":"36","author":"M Mahmoudi","year":"2018","unstructured":"Mahmoudi, M. Debugging nano-bio interfaces: systematic strategies to accelerate clinical translation of nanotechnologies. Trends Biotechnol. 36, 755\u2013769 (2018).","journal-title":"Trends Biotechnol."},{"key":"70859_CR60","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jconrel.2020.08.016","volume":"327","author":"S Adityan","year":"2020","unstructured":"Adityan, S., Tran, M., Bhavsar, C. & Wu, S. Y. Nano-therapeutics for modulating the tumour microenvironment: Design, development, and clinical translation. J. Control. Release. Off. J. Control. Release. Soc. 327, 512\u2013532 (2020).","journal-title":"J. Control. Release. Off. J. Control. Release. Soc."},{"key":"70859_CR61","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med. 27, 1250\u20131261 (2021).","journal-title":"Nat. Med."},{"key":"70859_CR62","doi-asserted-by":"crossref","unstructured":"Peranzoni, E. et al. Ex vivo imaging of resident CD8 T lymphocytes in human lung tumor slices using confocal microscopy. J. Vis. Exp. (2017).","DOI":"10.3791\/55709"},{"key":"70859_CR63","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni, E. et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc. Natl. Acad. Sci. USA 115, E4041\u2013e4050 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70859_CR64","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41590-022-01398-6","volume":"24","author":"S Ma","year":"2023","unstructured":"Ma, S. et al. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8(+) T cells. Nat. Immunol. 24, 255\u2013266 (2023).","journal-title":"Nat. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70859-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70859-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70859-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:02:06Z","timestamp":1778338926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70859-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70859"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70859-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4082"}}